Tosedostat
- Generic Name
- Tosedostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30N2O6
- CAS Number
- 238750-77-1
- Unique Ingredient Identifier
- KZK563J2UW
- Background
Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others.
Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel. It entered the clinical trial in patients with haematological malignancies.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Clinical Efficacy and Safety of Tosedostat in MDS
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 12
- Registration Number
- NCT02452346
- Locations
- ๐บ๐ธ
Weill Cornell Medical College, New York, New York, United States
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT02352831
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT01636609
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Secondary Myelodysplastic SyndromesAcute Myeloid Leukemia With Multilineage DysplasiaSecondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Previously Treated Myelodysplastic SyndromesUntreated Adult Acute Myeloid Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01567059
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Chroma Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT00780598
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
๐จ๐ฆPrincess Margaret Hopsital, Toronto, Ontario, Canada
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.